Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis

Amyloid

Volumn 20, Issue 4, 2013, Pages 212-220

  Damy, Thibaud ^a,d,e,f   Deux, Jean François ^b,d,e,f   Moutereau, Stéphane ^a,d,e   Guendouz, Soulef ^a,d,e,f   Mohty, Dania ^c   Rappeneau, Stéphane ^a,d,e,f   Guellich, Aziz ^a,f   Hittinger, Luc ^a,d,e,f   Loric, Sylvain ^a,d,e   Lefaucheur, Jean Pascal ^b,d,e,f   Plante Bordeneuve, Violaine ^a,f  

^a HENRI MONDOR HOSPITAL   (France)

^b Department of Radiology ^*  (France)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ PARIS EST   (France)

^e INSERM   (France)

^f RESEAU AMYLOSE Mondorien (Amyloidosis Network)   (France)

Author keywords

Cardiac amyloidosis; Cardiac markers; Echocardiography; Natriuretic peptide; Speckle tracking; Transthyretin; Troponin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; PREALBUMIN; TROPONIN T;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; GENE MUTATION; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AMYLOID NEUROPATHIES, FAMILIAL; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; TROPONIN T;

EID: 84888018630     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2013.825240     Document Type: Article

References (33)

1. Falk R, Comenzo R, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909.
2. Falk R, Skinner M. The systemic amyloidoses: an overview. Adv Intern Med 2000;45:107-37.
3. Duston M, Skinner M, Shirahama T, Cohen A. Diagnosis of amyloidosis: analysis of four years' experience. Am J Med 1987;82: 412-4.
4. Shah K, Inoue Y, Mehra M. Amyloidosis and the heart: a comprehensive review. Arch Intern Med 2006;166:1805-13.
5. Ando Y, Nakamura M, Araki S. Transthyretinrelated familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057-62.
6. Dubrey S, Cha K, Skinner M, LaValley M, Falk R. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997;78: 74-82.
7. Rapezzi C, Merlini G, Quarta C, Riva L, Longhi S, Leone O, Salvi F, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203-12.
8. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-5.
9. Hlatky M, Heidenreich P. The value of BNP testing. Arch Intern Med 2006;166:1063-4.
10. Gray J. The use of B-type natriuretic peptide to diagnose congestive heart failure. Clin Lab Sci 2006;19:214-7.
11. Dispenzieri A, Kyle R, Gertz M, Therneau T, Miller W, Chandrasekaran K, McConnell JP, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003;361:1787-9.
12. Kristen A, Giannitsis E, Lehrke S, Hegenbart U, Konstandin M, Lindenmaier D, Merkle C, et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 2010;116:2455-61.
13. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-63.
14. Devereux RB, de Simone G, Koren MJ, Roman MJ, Laragh JH. Left ventricular mass as a predictor of development of hypertension. Am J Hypertens 1991;4:603S-7S.
15. Damy T, Viallet C, Lairez O, Deswarte G, Paulino A, Maison P, Vermes E, et al. Comparison of four right ventricular systolic echocardiographic parameters to predict adverse outcomes in chronic heart failure. Eur J Heart Fail 2009;11:818-24.
16. Youden W. An index for rating diagnostic tests. Cancer 1950;3: 32-5.
17. Juneblad K, Naslund A, Olofsson B, Suhr O. Outcome of exercise electrocardiography in familial amyloidotic polyneuropathy patients, Portuguese type, under evaluation for liver transplantation. Amyloid 2004;11:208-13.
18. Dokainish H. Tissue Doppler imaging in the evaluation of left ventricular diastolic function. Curr Opin Cardiol 2004;19:437-41.
19. Nahum J, Bensaid A, Dussault C, Macron L, Clemence D, Bouhemad B, Monin JL, et al. Impact of longitudinal myocardial deformation on the prognosis of chronic heart failure patients. Circ Cardiovasc Imaging 2010;3:249-56.
20. Liu D, Niemann M, Hu K, Herrmann S, Stork S, Knop S, Ertl G, et al. Echocardiographic evaluation of systolic and diastolic function in patients with cardiac amyloidosis. Am J Cardiol 2011; 108:591-8.
21. Vasan R. Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations. Circulation 2006;113:2335-62.
22. Nagueh S, Middleton K, Kopelen H, Zoghbi W, Quinones M. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997;30:1527-33.
23. Nagueh S, Lakkis N, Middleton K, Spencer W, Zoghbi W, Quinones M. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation 1999;99: 254-61.
24. Nagueh S, Appleton C, Gillebert T, Marino P, Oh J, Smiseth O, Waggoner AD, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107-133.
25. Takemura G, Takatsu Y, Doyama K, Itoh H, Saito Y, Koshiji M, Ando F, et al. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol 1998;15:754-65.
26. Nordlinger M, Barbarajean Magnani M, Skinner M, Falk R. Is Elevated Plasma B-Natriuretic Peptide in Amyloidosis Simply a Function of the Presence of Heart Failure? Am J Cardiol 2005;96: 982-4.
27. Lehrke S, Steen H, Kristen A, Merten C, Lossnitzer D, Dengler T, Katus HA, et al. Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis. Amyloid 2009;16:187-95.
28. Suhr O, Anan I, Backman C, Karlsson A, Lindqvist P, Mo rner S, Waldenstrom A. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med 2008; 263:294-301.
29. Thygesen K, Alpert J, White HD, Infarction JEAAWTFftRoM. Universal definition of myocardial infarction. Circulation 2007; 116:2634-53.
30. Jaffe A, Ravkilde J, Roberts R, Naslund U, Apple F, Galvani M, Katus H. It's time for a change to a troponin standard. Circulation 2000;102:1216-20.
31. Katus H, Remppis A, Neumann F, Scheffold T, Diederich K, Vinar G, Noe A, et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation 1991;83:902-12.
32. Steen H, Giannitsis E, Futterer S, Merten C, Juenger C, Katus H. Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function. J Am Coll Cardiol 2006;48:2192-4.
33. Miller W, Wright R, Mc Gregor C. Troponin levels in patients with amyloid cardiomyopathy undergoing cardiac transplantation. Am J Cardiol 2001;88:813-5.